ROCKVILLE, Md., Nov. 3, 2020 /PRNewswire/ -- Synthetic Biologics,
Inc. (NYSE American: SYN), a diversified clinical-stage company
leveraging the microbiome to develop therapeutics designed to
prevent and treat gastrointestinal (GI) diseases in areas of high
unmet need, announced today that the Company intends to release its
operational highlights and financial results for the quarter ended
September 30, 2020 on Tuesday, November 10, 2020, and to host a
conference call the same day at 4:30 p.m.
ET. The dial-in information for the call is as follows:
U.S. (toll free): 1-888-347-5280
International: +1-412-902-4280
Participants are asked to dial in 15 minutes before the start of
the call to register. The call will also be webcast over the
Internet at https://www.webcaster4.com/Webcast/Page/1096/38296. An
archived replay of the call will be available for approximately
ninety (90) days at the same URL,
https://www.webcaster4.com/Webcast/Page/1096/38296 beginning
approximately one hour after the call's conclusion.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is a
clinical-stage company leveraging the microbiome to develop
therapeutics designed to prevent and treat gastrointestinal (GI)
diseases in areas of high unmet need. The Company's lead clinical
candidates are: (1) SYN-004 (ribaxamase) which is designed to
degrade certain commonly used intravenous (IV) beta-lactam
antibiotics within the gastrointestinal (GI) tract to prevent
microbiome damage, C. difficile infection (CDI), overgrowth
of pathogenic organisms, the emergence of antimicrobial resistance
(AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic
hematopoietic cell transplant (HCT) recipients, and (2) SYN-010,
which is intended to reduce the impact of methane-producing
organisms in the gut microbiome to treat an underlying cause of
irritable bowel syndrome with constipation (IBS-C). The Company is
also advancing SYN-020, an oral formulation of the enzyme
intestinal alkaline phosphatase (IAP) to treat both local GI and
systemic diseases. For more information, please visit Synthetic
Biologics' website at www.syntheticbiologics.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-2020-third-quarter-operational-highlights-and-financial-results-on-november-10-2020-301165934.html
SOURCE Synthetic Biologics, Inc.